Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Bacigalupo, Andrea  [Clear All Filters]
Journal Article
Ali H, Bacigalupo A. 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. Am J Hematol. 2024.
Fiz F, Marini C, Campi C, Massone AMaria, Podestà M, Bottoni G, Piva R, Bongioanni F, Bacigalupo A, Piana M, et al. Allogeneic cell transplant expands bone marrow distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. Blood. 2015.
Sorà F, Di Grazia C, Chiusolo P, Raiola AMaria, Bregante S, Mordini N, Olivieri A, Iori APaola, Patriarca F, Grisariu S, et al. Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with Busulfan Fludarabine (BUFLU) or Thiotepa Busulfan Fludarabine (TBF): a retrospective study. Biol Blood Marrow Transplant. 2019.
Bacigalupo A. Allogeneic stem cell transplantation for nonmalignant diseases. Curr Opin Hematol. 2016.
Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MChiara, Bosi A, Russo D, Narni F, Messina G, et al. Busulfan or thiotepa based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group. Biol Blood Marrow Transplant. 2018.
Metafuni E, Cavattoni IMaria, Lamparelli T, Raiola AMaria, Ghiso A, Galaverna F, Gualandi F, Di Grazia C, Dominietto A, Varaldo R, et al. Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation. Blood Adv. 2021.
Bacigalupo A, Sica S, van Lint MTeresa. Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention. Haematologica. 2016;101(5):e214-e215.
Chiusolo P, Bregante S, Giammarco S, Lamparelli T, Casarino L, Dominietto A, Raiola AMaria, Metafuni E, Di Grazia C, Gualandi F, et al. Full Donor Chimerism After Allogeneic Hematopoietic Stem Cells Transplant For Myelofibrosis: The Role Of The Conditioning Regimen. Am J Hematol. 2020.
Gambella M, Bregante S, Raiola AMaria, Varaldo R, Ghiso A, Schiavetti I, Carmisciano L, Bacigalupo A, Angelucci E. Haploidentical hemopoietic cell transplantation for myelofibrosis, in ruxolitinib era. Transplant Cell Ther. 2022.
Sureda A, Carpenter PA, Bacigalupo A, Bhatt VRaj, De La Fuente J, Ho A, Kean L, Lee JWook, Sánchez-Ortega I, Savani BN, et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024.
Giammarco S, Sica S, Metafuni E, Limongiello MAssunta, Valentini CGiovanna, Sorà F, Marra JDonald, Bacigalupo A, Teofili L, Chiusolo P. Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center. Transfus Apher Sci. 2023:103708.
Mariotti J, Raiola AMaria, Evangelista A, Carella AMichele, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.
Mariotti J, Raiola AMaria, Evangelista A, Harbi S, Patriarca F, Carella MAngelo, Martino M, Risitano A, Busca A, Giaccone L, et al. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernández-Boluda JCarlos, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.
Chiodi S, Spinelli S, Bruzzi P, Anserini P, Di Grazia C, Bacigalupo A. Menstrual patterns, fertility and main pregnancy outcomes after allogeneic haematopoietic stem cell transplantation. J Obstet Gynaecol. 2016:1-6.
Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, et al. MPD-RC 101 prospective study of reduced intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014.
Piccirillo N, Putzulu R, Metafuni E, Massini G, Fatone F, Corbingi A, Giammarco S, Limongiello MAssunta, Di Giovanni A, Zini G, et al. Peripheral Blood Allogeneic Stem Cell Mobilization: Can We Predict a Suboptimal Mobilization?. Transfus Med Rev. 2023;37(2):150725.
Autore F, Piccirillo N, Nozza A, Innocenti I, Putzulu R, Chiusolo P, Sora' F, Zini G, Bacigalupo A, Castagna L, et al. Peripheral blood hemopoietic stem cell mobilization regimens in POEMS syndrome: a retrospective study at two haematological Italian centres. Biol Blood Marrow Transplant. 2019.
Porta MGDella, Alessandrino EPaolo, Bacigalupo A, van Lint MTeresa, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood. 2014.
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167.
Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JLuiz, Bruno B, Castagna L, Moiseev ISergeevich, Vitek A, et al. The timing of post-transplant cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the ALWP of the EBMT. Biol Blood Marrow Transplant. 2020.
Alotaibi H, Aljurf M, de Latour R, Alfayez M, Bacigalupo A, Fakih REl, Schrezenmeier H, Ahmed SOsman, Gluckman E, Iqbal S, et al. Upfront Alternative Donor Transplant Versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack Fully HLA Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies. on Behalf of the Severe Aplastic Anemia W. Transplant Cell Ther. 2021.
Autore F, Bramanti S, Lessi F, Innocenti I, Galli E, Rocchi S, Ribolla R, Derudas D, Oliva S, Stefanoni P, et al. Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome?. Haematologica. 2023.